NASDAQ: ELYM - Eliem Therapeutics, Inc.

Altı ay boyunca karlılık: +89.59%
Sektör: Healthcare

Promosyon programı Eliem Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.

Daha fazla ayrıntı
The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

EBITDA -0.0019
EV/EBITDA 10.99
IPO date 2021-08-10
ISIN US28658R1068
Industry Biotechnology
P/BV 1.64
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://eliemtx.com
Цена ао 2.71
Число акций ао 0.02699 млрд
Günlük fiyat değişimi: -0.1957% (5.11)
Haftalık fiyat değişimi: +2% (5)
Aylık fiyat değişimi: -29.56% (7.24)
3 ayda fiyat değişimi: -23.08% (6.63)
Altı ayda fiyat değişimi: +89.59% (2.69)
Yıllık fiyat değişimi: +101.58% (2.53)
3 yılda fiyat değişimi: -69.33% (16.63)
Yılbaşından bu yana fiyat değişimi: +99.22% (2.56)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 0.7136 10
P/E 0 0
EV/EBITDA 0.3969 10
Toplam: 5

Yeterlik

İsim Anlam Seviye
ROA, % -31.79 0
ROE, % -32.64 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0087 10
Toplam: 9.2

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 2019.74 10
karlılık EPS, % 134.3 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
RA Capital Management, L.P. 13150849 47.44
Bml Capital Management, LLC 2180000 7.86
Driehaus Capital Management, LLC 811680 2.93
Vanguard Group Inc 310486 1.12
Atom Investors LP 78276 0.28
Geode Capital Management, LLC 66626 0.24
Bridgeway Capital Management, Inc. 55223 0.2
Northern Trust Corporation 48712 0.18
Blackrock Inc. 31145 0.11
Tudor Investment Corporation 29490 0.11

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
Avantis U.S Small Cap Equity ETF 0.00871 27.774101036841 1.68271
Dimensional U.S. Core Equity 2 ETF 0.00015 30.755198832543 1.47098
ProShares Hedge Replication ETF 0.00037 5.9237999659878 1.47892
iShares Neuroscience and Healthcare ETF 0.8148 19.720292847757 0.03
iShares Micro-Cap ETF 0.06271 29.340359461748 1.54048
iShares Russell 2000 Growth ETF 0.00105 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00133 89.821266282945 1.47873
Vanguard Russell 2000 ETF 0 30.781541744465 1.48801



Süpervizör İş unvanı Ödeme Doğum yılı
Ms. Emily Pimblett Chief Accounting Officer N/A 1984 (40 yıllar)
Ms. Jo Palmer-Phillips Ph.D. Chief Development Officer N/A
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc CEO, President & Director 1976 (48 yıllar)
Dr. Brett Kaplan M.B.A., M.D. COO & Principal Financial Officer 1974 (50 yıllar)
Dr. Nishi Rampal M.D. Senior Vice President of Clinical Development

Adres: United States, Redmond. WA, 23515 NE Novelty Hill Road - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://eliemtx.com